Status:
COMPLETED
A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Non-Alcoholic Steatohepatitis
Eligibility:
All Genders
21-75 years
Phase:
PHASE2
Brief Summary
The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatit...
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
- Male or female between 21 and 75 years old
- Body Mass Index (BMI) of 25 or more
Exclusion
- Chronic Liver disease other than NASH
- Uncontrolled diabetes
- Any major surgery within 6 weeks of screening
- Unable to self-administer under the skin injections
- Any bone trauma, fracture or bone surgery within 8 weeks of screening
Key Trial Info
Start Date :
May 8 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 19 2017
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT03400163
Start Date
May 8 2015
End Date
June 19 2017
Last Update
February 26 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107
2
Texas Liver Institute
San Antonio, Texas, United States, 78215